1. Dinitrosyl iron complexes (DNICs) as inhibitors of the SARS-CoV-2 main protease.
- Author
-
Pectol DC, DeLaney CR, Zhu J, Mellott DM, Katzfuss A, Taylor ZW, Meek TD, and Darensbourg MY
- Subjects
- Dose-Response Relationship, Drug, Enzyme Inhibitors chemistry, Humans, Iron chemistry, Models, Molecular, Molecular Structure, Nitrogen Oxides chemistry, SARS-CoV-2 enzymology, Enzyme Inhibitors pharmacology, Iron pharmacology, Nitrogen Oxides pharmacology, Peptide Hydrolases metabolism, SARS-CoV-2 drug effects
- Abstract
By repurposing DNICs designed for other medicinal purposes, the possibility of protease inhibition was investigated in silico using AutoDock 4.2.6 (AD4) and in vitro via a FRET protease assay. AD4 was validated as a predictive computational tool for coordinatively unsaturated DNIC binding using the only known crystal structure of a protein-bound DNIC, PDB- (calculation RMSD = 1.77). From the in silico data the dimeric DNICs TGTA-RRE, [(μ-S-TGTA)Fe(NO)
2 ]2 (TGTA = 1-thio-β-d-glucose tetraacetate) and TG-RRE, [(μ-S-TG)Fe(NO)2 ]2 (TG = 1-thio-β-d-glucose) were identified as promising leads for inhibition via coordinative inhibition at Cys-145 of the SARS-CoV-2 Main Protease (SC2Mpro ). In vitro studies indicate inhibition of protease activity upon DNIC treatment, with an IC50 of 38 ± 2 μM for TGTA-RRE and 33 ± 2 μM for TG-RRE. This study presents a simple computational method for predicting DNIC-protein interactions; the in vitro study is consistent with in silico leads.- Published
- 2021
- Full Text
- View/download PDF